Regulating disease or disorder characterized by esophageal epithelial proliferation through secreted frizzled-related protein 1 (sfrp1)
OwnerSimon P. HOGAN, Sahiti Marellainventors
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to compositions, methods, and agents directed to treating diseases and disorders characterized by abnormal esophageal epithelial proliferation and/or growth. In some embodiments, the compositions, methods, and agents comprise a SFRP1 activator or a composition thereof and/or SFRP1, a biologically active fragment or variant thereof, or a nucleic acid encoding SFRP1 or a biologically active fragment or variant thereof. In some embodiments, the compositions, methods, and agents comprise a signal transducer and activator of transcription 3 (STAT3) inhibitor or a composition thereof.
Claims48
A method of attenuating esophageal epithelial proliferation disease in a subject in need thereof, the method comprising increasing the level and/or the activity of secreted frizzled-related protein 1 (SFRP1) in the subject by administering to the subject an effective amount of:
- a SFRP1 activator or a composition thereof;
- and/or
- SFRP1, a biologically active fragment or variant thereof, or a nucleic acid encoding SFRP1 or a biologically active fragment or variant thereof.
A method of treating or preventing an epithelial cell disease or disorder in a subject comprising administering to the subject a therapeutically or prophylactically effective amount of a signal transducer and activator of transcription 3 (STAT3) inhibitor or a composition thereof to the subject.
A method of treating or preventing a disease or disorder in a subject comprising administering to the subject a therapeutically or prophylactically effective amount of at least one signal transducer and activator of transcription 3 (STAT3) inhibitor or a composition thereof,
- wherein the disease or disorder is characterized by aberrant esophageal epithelial proliferation, and
- wherein the epithelial proliferation occurs within a suprabasal epithelial cell population of cells expressing one or more inflammatory genes selected from TNFAIP6, POSTN, CCL26, and ALOX15.
A method of treating or preventing a disease or disorder in a subject, comprising administering to the subject an effective amount of secreted frizzled-related protein 1 (SFRP1), a biologically active fragment or variant thereof, or a nucleic acid encoding SFRP1 or a biologically active fragment or variant thereof.
Use of a SFRP1 activator or a composition thereof;
- and/or SFRP1, a biologically active fragment or variant thereof, or a nucleic acid encoding SFRP1 or a biologically active fragment or variant thereof, in treating a disease or disorder characterized by esophageal epithelial proliferation.
Use of a SFRP1 activator or a composition thereof;
- and/or SFRP1, a biologically active fragment or variant thereof, or a nucleic acid encoding SFRP1 or a biologically active fragment or variant thereof, in treating a disease or disorder characterized by esophageal epithelial remodeling.
Use of a SFRP1 activator or a composition thereof;
- and/or SFRP1, a biologically active fragment or variant thereof, or a nucleic acid encoding SFRP1 or a biologically active fragment or variant thereof, in regulating esophageal epithelial proliferation.
Use of a signal transducer and activator of transcription 3 (STAT3) inhibitor or a composition thereof for treating or preventing a disease or disorder in a subject comprising administering to the subject a therapeutically or prophylactically effective amount of a STAT3 inhibitor or a composition thereof to the subject, wherein the disease or disorder is an esophageal epithelial proliferation disease.
Dependencies are inferred from the claim text.